A, Overall survival (OS) and progression-free survival (PFS) for the 106 evaluable patients. B, change in volume of targeted (irradiated) lesion with best response during protocol C, change in volume of single unirradiated lesion with best response per patient, during protocol. For reference, cut-off points from the Immune-Related Response Criteria (irRC) guidelines are provided in the waterfall plots for partial response (irPR) and progressive disease (irPD).